Literature DB >> 1940945

Treating organic abulia with bromocriptine and lisuride: four case studies.

K Barrett1.   

Abstract

Abulia refers to an impairment of will, or the inability to initiate behaviour and action. There are reports of successful treatment of akinetic mutism, the most severe form of abulia, with bromocriptine. Four case studies are presented describing the successful treatment of abulia at a lesser severity than akinetic mutism with bromocriptine. Abulia was caused by brain damage due to alcohol in two cases, Wilson's disease and basal ganglia infarct in one each. Maximum bromocriptine dose varied from 25-70 mg. All improved considerably. Withdrawal or reduction of medication in three produced deterioration. The prescription of a neuroleptic drug had a similar effect in the fourth. One patient with a previous history developed a depressive relapse and so the drug was withdrawn and lisuride introduced. This produced a similar improvement. These cases highlight the value of identifying the syndrome of organic abulia and suggest that dopamine agonists may have a place in its treatment, though controlled studies are needed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1940945      PMCID: PMC1014478          DOI: 10.1136/jnnp.54.8.718

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  7 in total

1.  Pharmacotherapy for aphasia.

Authors:  M L Albert; D L Bachman; A Morgan; N Helm-Estabrooks
Journal:  Neurology       Date:  1988-06       Impact factor: 9.910

2.  The effect of bromocriptine on speech dysfunction in patients with diffuse brain injury (akinetic mutism).

Authors:  M L Crismon; A Childs; R E Wilcox; N Barrow
Journal:  Clin Neuropharmacol       Date:  1988-10       Impact factor: 1.592

3.  Mesencephalic dopamine neurons projecting to neocortex.

Authors:  O Lindvall; A Björklund; R Y Moore; U Stenevi
Journal:  Brain Res       Date:  1974-12-06       Impact factor: 3.252

4.  Akinetic mutism from hypothalamic damage: successful treatment with dopamine agonists.

Authors:  E D Ross; R M Stewart
Journal:  Neurology       Date:  1981-11       Impact factor: 9.910

5.  Dual action on central dopamine function of transdihydrolisuride, a 9, 10-dihydrogenated analogue of the ergot dopamine agonist lisuride.

Authors:  H Wachtel; R Dorow
Journal:  Life Sci       Date:  1983-01-24       Impact factor: 5.037

6.  Akinetic mutism: pharmacologic probe of the dopaminergic mesencephalofrontal activating system.

Authors:  H C Echiverri; W O Tatum; T A Merens; S B Coker
Journal:  Pediatr Neurol       Date:  1988 Jul-Aug       Impact factor: 3.372

7.  Honored guest presentation: abulia minor vs. agitated behavior.

Authors:  C M Fisher
Journal:  Clin Neurosurg       Date:  1983
  7 in total
  7 in total

1.  Dopamine agonists can improve pure apathy associated with lesions of the prefrontal-basal ganglia functional system.

Authors:  Carlo Blundo; Carmela Gerace
Journal:  Neurol Sci       Date:  2015-01-21       Impact factor: 3.307

2.  Abulia following an episode of cardiac arrest.

Authors:  Vismay Dinesh Naik
Journal:  BMJ Case Rep       Date:  2015-07-01

3.  Motivational deficits after brain injury: effects of bromocriptine in 11 patients.

Authors:  J H Powell; S al-Adawi; J Morgan; R J Greenwood
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

Review 4.  Apathy and the basal ganglia.

Authors:  Richard Levy; Virginie Czernecki
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

Review 5.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

Review 6.  Agomelatine: an agent against anhedonia and abulia?

Authors:  J Thome; P Foley
Journal:  J Neural Transm (Vienna)       Date:  2013-12-06       Impact factor: 3.575

7.  The human frontal lobes and frontal network systems: an evolutionary, clinical, and treatment perspective.

Authors:  Michael Hoffmann
Journal:  ISRN Neurol       Date:  2013-03-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.